Status and phase
Conditions
Treatments
About
This study is a multicenter, prospective, interventional study. It does not have a control group. All participants will receive 160 mg valsartan for 8 weeks. Among them, the patients with persistent proteinuria (defined as proteinuria more than 1 g/g after 8 weeks treatment of valsartan) will receive 320 mg valsartan for further 16 weeks. Participants who did not receive any ACEI or ARB previously will have a titration period for 4 weeks (80 mg for 4 weeks, 160 mg for 4 weeks, and then 320 mg for 16 weeks).
The investigators will evaluate the change of urinary angiotensinogen excretion between at baseline, at 8 weeks, and 24 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Chronic kidney disease patients with
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
500 participants in 1 patient group
Loading...
Central trial contact
Yoon-Goo Kim, Professor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal